Preventing vision loss in age-related macular degeneration
Inhibiting Neovascularization and Subretinal Fibrosis in Neovascular Age-Related Macular Degeneration
This study is looking into how age-related macular degeneration (AMD) can lead to worsening vision due to a condition called subretinal fibrosis, and it's trying to find new treatments that could help protect your eyesight and improve your overall vision.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Utah NIH-funded |
| Lab location | 1 site (Salt Lake City, United States) |
| Project ID | NIH-10873235 on NIH RePORTER |
What this research studies
This research focuses on age-related macular degeneration (AMD), a leading cause of blindness, particularly its neovascular form which causes severe vision loss. The study aims to understand the molecular mechanisms that lead to subretinal fibrosis, a condition that worsens vision despite existing treatments. By exploring how certain cellular transitions contribute to this fibrosis, the research seeks to develop new drug therapies that can inhibit these processes and improve patient outcomes. Patients may benefit from innovative treatments that not only target the neovascularization but also prevent further damage to the retina.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults aged 21 and older who are diagnosed with neovascular age-related macular degeneration.
Not a fit: Patients with non-neovascular forms of age-related macular degeneration or other unrelated eye conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new therapies that significantly reduce vision loss in patients with age-related macular degeneration.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in other ocular conditions, suggesting potential for success in this novel approach.
Where this research is happening
Salt Lake City, United States
- University of Utah — Salt Lake City, United States (Active)
Researchers
- Principal investigator: Zhu, Weiquan (Wendy) — University of Utah
- Study coordinator: Zhu, Weiquan (Wendy)
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.